RCS - PureTech Health PLC - PRTC To Showcase Deupirfenidone at ATS Conference

Puretech HealthAnnouncement

13/05/2026 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260513:nRSM1044Ea&default-theme=true

RNS Number : 1044E  PureTech Health PLC  13 May 2026

13 May 2026

PureTech Health plc

 

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society
International Conference

 

Presentations to highlight differentiated approach to advancing
deupirfenidone, reinforcing its potential to serve as a new standard of care
within the evolving idiopathic pulmonary fibrosis treatment landscape

 

PureTech Health plc (https://puretechhealth.com/)  (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company
dedicated to giving life to science and transforming innovation into value,
today announced presentations showcasing its deupirfenidone (LYT-100) program
at the upcoming American Thoracic Society (ATS) International Conference,
taking place in Orlando, Florida, from May 15-20, 2026. Deupirfenidone is an
investigational therapy being advanced by PureTech's Founded Entity, Celea
Therapeutics (Celea), as a potential new standard of care for the treatment of
idiopathic pulmonary fibrosis (IPF).

 

"The SURPASS-IPF program reflects a broader shift in how the field is
beginning to think about IPF treatment," said Toby Maher, MD, PhD, Professor
of Medicine and Director of Interstitial Lung Disease at Keck School of
Medicine, University of Southern California, Los Angeles, who will present
details around the SURPASS-IPF Phase 3 trial. "Historically, clinicians and
patients have often accepted modest efficacy because therapeutic options were
limited. What makes the Phase 3 SURPASS-IPF trial particularly compelling is
not only the head-to-head superiority design against a standard of care, but
also the strength and consistency of the underlying dataset supporting it. The
previously completed Phase 2b ELEVATE IPF trial included an active comparator
arm (pirfenidone) that provided important clinical context, while the Qureight
analyses further demonstrate that the enrolled population was highly
representative of a well-characterized real-world IPF population.
Collectively, these elements increase confidence as the program advances into
Phase 3 and support the broader hypothesis that greater preservation of lung
function may be achievable in IPF."

 

Presentations include:

 Industry Program
 Title:                Raising the Bar with SURPASS-IPF: The First Phase 3 Head-to-Head Superiority
                       Trial in IPF Testing Deupirfenidone vs. Pirfenidone
 Presenter:            Toby Maher, MD, PhD
 Date & Time:          Monday, May 18, 2026 | 11:05am EDT
 Location:             Innovation Hub 3

 Poster Presentations
 Title:                SURPASS-IPF: Study Design of a Phase 3, Head-to-Head Trial of Deupirfenidone
                       Compared to Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (P807)
 Date & Time:          Sunday, May 17, 2026 | 11:30am EDT
 Location:             Area E, Halls WA2-WA3

 Title:                Deep Learning-based HRCT Assessment Of Baseline Disease Severity in the
                       Deupirfenidone Elevate IPF Trial: Comparison With A Well-Characterised IPF
                       Population (P708)
 Date & Time:          Monday, May 18, 2026 | 9:15am EDT
 Location:             W314

 

 

"A decade after the introduction of first-generation antifibrotics, enhanced
efficacy remains one of the most important unmet needs for people living with
IPF," said Camilla Graham, MD, MPH, Senior Vice President of Medical Affairs
at PureTech. "Our ATS presentations collectively reflect Celea's strategy to
challenge longstanding assumptions in IPF drug development - from designing
the first industry-sponsored head-to-head superiority trial in IPF against an
approved antifibrotic, to leveraging advanced imaging technologies to better
characterize disease severity and strengthen confidence in the translatability
of our Phase 2b findings into Phase 3. Together, these presentations reinforce
our belief that deupirfenidone has the potential to meaningfully improve upon
the efficacy achieved with current standard-of-care therapies."

 

About Deupirfenidone (LYT-100)

Deupirfenidone (LYT-100) is in development as a potential new standard of care
for the treatment of idiopathic pulmonary fibrosis (IPF). It is a
next-generation antifibrotic and a deuterated form of pirfenidone, one of
three FDA-approved therapies for IPF. The uptake of and adherence to approved
antifibrotics has historically been limited by a tradeoff between modest
efficacy and tolerability, and only ~25% of people with IPF in the U.S. had
ever received treatment as of 2019. 1  (#_ftn1)

 

Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE
IPF trial, published in The American Journal of Respiratory and Critical Care
Medicine (https://doi.org/10.1093/ajrccm/aamag155) (AJRCCM), deupirfenidone
demonstrated the potential to stabilize lung function decline over at least 26
weeks as a monotherapy while maintaining a favorable safety and tolerability
profile. Initial data from an ongoing open-label extension study suggest this
effect may be sustained through at least 52 weeks. These findings support the
potential for deupirfenidone to offer a meaningful advance for people living
with this progressive and deadly disease. Beyond IPF, deupirfenidone may also
address multiple underserved fibrotic conditions, including progressive
fibrosing interstitial lung diseases.

 

About Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal lung
disease characterized by irreversible scarring of lung tissue that leads to a
steady decline in lung function. Median survival following diagnosis is
estimated to be two to five years, 2  (#_ftn2) and currently there is no cure.

 

About Celea Therapeutics

Celea Therapeutics is dedicated to advancing transformative treatments for
people with serious respiratory diseases. Drawn from the Latin word for "sky,"
the name reflects the company's mission to rise above the status quo and
deliver therapies that change lives. The company's lead program,
deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the
potential to set a new standard of care for idiopathic pulmonary fibrosis
(IPF) and other fibrotic lung diseases.

 

Celea was founded by and is currently a wholly-owned subsidiary of PureTech
Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company dedicated to
giving life to science. PureTech's innovative R&D model drives the
creation of Founded Entities like Celea, enabling the advancement of highly
promising medicines to patients in a capital-efficient manner. For more
information, please visit www.celeatx.com.

 

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving
life to science and transforming innovation into value. We do this through a
proven, capital-efficient R&D model focused on opportunities with
validated pharmacology and untapped potential to address significant patient
needs. This strategy has produced dozens of therapeutic candidates, including
three that have received U.S. FDA approval. By identifying, shaping, and
de-risking these high-conviction assets, and scaling them through dedicated
structures backed by external capital, we accelerate their path to patients
while creating sustainable value for shareholders.

 

For more information, visit www.puretechhealth.com or connect with us on
LinkedIn (https://www.linkedin.com/company/puretech-health/) and X (formerly
Twitter) @puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to the deupirfenidone (LYT-100)
development program and development plans, its potential benefits to patients,
plans for discussions with regulatory authorities, the further development of
the program, future presentation of additional data from the trial and our
future prospects, developments and strategies. The forward-looking statements
are based on current expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual results,
performance and achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other important
factors described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2024, filed with the SEC and in our
other regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
Company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press release.
Except as required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.

 

Contact:

PureTech
Public Relations
publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations
IR@puretechhealth.com (mailto:IR@puretechhealth.com)

UK/EU Media
Ben Atwell, Rob Winder

+44 (0) 20 3727 1000
puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

US Media
Justin Chen
jchen@tenbridgecommunications.com (mailto:jchen@tenbridgecommunications.com)

 1  (#_ftnref1) Dempsey, T. M., Payne, S., Sangaralingham, L., Yao, X., Shah,
N. D., & Limper, A. H. (2021). Adoption of the antifibrotic medications
pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis.
Annals of the American Thoracic Society, 18(7), 1121-1128.

 2  (#_ftnref2) Fisher, M., Nathan, S. D., Hill, C., Marshall, J.,
Dejonckheere, F., Thuresson, P., & Maher, T. M. (2017). Predicting life
expectancy for pirfenidone in idiopathic pulmonary fibrosis. Journal of
Managed Care & Specialty Pharmacy, 23(3-b Suppl), S17-S24.
https://doi.org/10.18553/jmcp.2017.23.3-b.s17

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUAAAUPQUUW



            Copyright 2019 Regulatory News Service, all rights reserved